Central India Chronicle

Janus kinase (JAK) Inhibitors Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Janus kinase (JAK) Inhibitors Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

February 23
17:15 2023
Janus kinase (JAK) Inhibitors Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Janus kinase (JAK) Inhibitors pipeline constitutes key companies continuously working towards developing Janus kinase (JAK) Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Janus kinase (JAK) Inhibitors Overview

Janus kinase (JAK) inhibitors are small molecules approximately 400 Da that could be administered as oral medicines. JAKs are phosphotransferases that bind to the intracellular domains of cytokine receptors and transmit signals to activate immune responses.

 

Janus kinase (JAK) Inhibitors Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Janus kinase (JAK) Inhibitors Market.

 

The Janus kinase (JAK) Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Janus kinase (JAK) Inhibitors Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Janus kinase (JAK) Inhibitors treatment therapies with a considerable amount of success over the years. Janus kinase (JAK) Inhibitors Key players such as – Aclaris Therapeutics, Pfizer, Celon Pharma, Theravance Biopharma, Reistone Biopharma, Concert Pharmaceuticals, Incyte Corporation, AbbVie, Eli Lilly and Company, and others, are developing therapies for the Janus kinase (JAK) Inhibitors treatment 
  • Janus kinase (JAK) Inhibitors Emerging therapies such as – ATI-2138, PF-07295324, EQ-121 EQRx, CPL409116, TD-0903, Ivarmacitinib, CTP-543, Povorcitinib, Upadacitinib, Baricitinib, and others are expected to have a significant impact on the Janus kinase (JAK) Inhibitors market in the coming years.   
  • In May 2022, US Food and Drug Administration (FDA) approved OLUMIANT (baricitinib) for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4-mg once daily for 14 days or until hospital discharge, whichever comes first
  • In June 2022, the US Food and Drug Administration approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata, a disorder that often appears as patchy baldness and affects more than 300,000 people in the U.S. each year
  • In October 2022, AbbVie announced that the Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) had been approved by the US Food and Drug Administration (FDA) for adults with non-radiographic axial spondyloarthritis (nr-axSpA) who have objective signs of inflammation and have had an inadequate response to or are intolerant of one or more tumor necrosis factor (TNF) inhibitors
  • In December 2022, Incyte Corporation initiated a Phase III, double-blind, randomized, placebo controlled, efficacy and safety study of povorcitinib (INCB054707) in participants with moderate to severe hidradenitis suppurativa.
  • In April 2021, Japan’s health ministry approved the use of rheumatoid arthritis drug Baricitinib for COVID-19 patients
  • In May 2021, Incyte Corporation initiated a Phase II, randomized, double-blind, placebo-controlled, dose ranging study of the efficacy and safety of INCB054707 followed by an extension period in participants with vitiligo

 

Route of Administration

Janus kinase (JAK) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Janus kinase (JAK) Inhibitors Pipeline Therapeutics Assessment

  • Janus kinase (JAK) Inhibitors Assessment by Product Type
  • Janus kinase (JAK) Inhibitors By Stage and Product Type
  • Janus kinase (JAK) Inhibitors Assessment by Route of Administration
  • Janus kinase (JAK) Inhibitors By Stage and Route of Administration
  • Janus kinase (JAK) Inhibitors Assessment by Molecule Type
  • Janus kinase (JAK) Inhibitors by Stage and Molecule Type

 

DelveInsight’s Janus kinase (JAK) Inhibitors Report covers around products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Emerging Janus kinase (JAK) Inhibitors Drugs Under Different Phases of Clinical Development Include:

  • ATI-2138 Aclaris Therapeutics
  • PF-07295324 Pfizer
  • EQ-121 EQRx
  • CPL409116 Celon Pharma
  • TD-0903 Theravance Biopharma
  • Ivarmacitinib Reistone Biopharma
  • CTP-543 Concert Pharmaceuticals
  • Povorcitinib Incyte Corporation
  • Upadacitinib AbbVie
  • Baricitinib Eli Lilly and Company

 

Get a Free Sample PDF Report to know more about Janus kinase (JAK) Inhibitors Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight

 

Janus kinase (JAK) Inhibitors Pipeline Analysis:

The Janus kinase (JAK) Inhibitors pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Janus kinase (JAK) Inhibitors with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Janus kinase (JAK) Inhibitors Treatment.
  • Janus kinase (JAK) Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Janus kinase (JAK) Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Janus kinase (JAK) Inhibitors market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Janus kinase (JAK) Inhibitors product details are provided in the report. Download the Janus kinase (JAK) Inhibitors pipeline report to learn more about the emerging Janus kinase (JAK) Inhibitors therapies

 

Janus kinase (JAK) Inhibitors Pipeline Market Drivers

  • Rising prevalence of chronic and autoimmune disease
  • Increasing research and development projects for the launch of new drugs

 

Janus kinase (JAK) Inhibitors Pipeline Market Barriers

  • High cost of treatment
  • Regulatory challenges in the launch of JAK inhibitors

 

Scope of Janus kinase (JAK) Inhibitors Pipeline Drug Insight    

  • Coverage: Global
  • Key Janus kinase (JAK) Inhibitors Companies: Aclaris Therapeutics, Pfizer, Celon Pharma, Theravance Biopharma, Reistone Biopharma, Concert Pharmaceuticals, Incyte Corporation, AbbVie, Eli Lilly and Company, and others
  • Key Janus kinase (JAK) Inhibitors Therapies: ATI-2138, PF-07295324, EQ-121 EQRx, CPL409116, TD-0903, Ivarmacitinib, CTP-543, Povorcitinib, Upadacitinib, Baricitinib, and others
  • Janus kinase (JAK) Inhibitors Therapeutic Assessment: Janus kinase (JAK) Inhibitors current marketed and Janus kinase (JAK) Inhibitors emerging therapies
  • Janus kinase (JAK) Inhibitors Market Dynamics: Janus kinase (JAK) Inhibitors market drivers and Janus kinase (JAK) Inhibitors market barriers 

 

Request for Sample PDF Report for Janus kinase (JAK) Inhibitors Pipeline Assessment and clinical trials

 

Table of Contents

1

Janus kinase (JAK) Inhibitors Report Introduction

2

Janus kinase (JAK) Inhibitors Executive Summary

3

Janus kinase (JAK) Inhibitors Overview

4

Janus kinase (JAK) Inhibitors- Analytical Perspective In-depth Commercial Assessment

5

Janus kinase (JAK) Inhibitors Pipeline Therapeutics

6

Janus kinase (JAK) Inhibitors Late Stage Products (Phase II/III)

7

Janus kinase (JAK) Inhibitors Mid Stage Products (Phase II)

8

Janus kinase (JAK) Inhibitors Early Stage Products (Phase I)

9

Janus kinase (JAK) Inhibitors Preclinical Stage Products

10

Janus kinase (JAK) Inhibitors Therapeutics Assessment

11

Janus kinase (JAK) Inhibitors Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Janus kinase (JAK) Inhibitors Key Companies

14

Janus kinase (JAK) Inhibitors Key Products

15

Janus kinase (JAK) Inhibitors Unmet Needs

16 

Janus kinase (JAK) Inhibitors Market Drivers and Barriers

17

Janus kinase (JAK) Inhibitors Future Perspectives and Conclusion

18

Janus kinase (JAK) Inhibitors Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Download Sample PDF Report to know more about Janus kinase (JAK) Inhibitors drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting